Summary of Key Information:
Reporting Period (Quarter/Year): Quarter ended June 30, 2026 (Q1 FY27)
Nature of Filing / Announcement: Outcome of Board Meeting and Disclosures under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Audit Opinion:
Limited Review Report issued by Statutory Auditors - No modified opinion, but with Emphasis of Matter paragraphs
Key Financial Highlights [All amounts in ₹ millions]:
Standalone Results:
Revenue from Operations: ₹1,014.02 (Q1 FY27) vs ₹632.57 (Q1 FY26) - 60.3% YoY increase
Total Income: ₹1,043.66 (Q1 FY27) vs ₹653.65 (Q1 FY26) - 59.7% YoY increase
Net Profit: ₹98.34 (Q1 FY27) vs ₹59.69 (Q1 FY26) - 64.8% YoY increase
EPS: Basic ₹0.82, Diluted ₹0.80
Other Equity: Not specified in standalone results
Cash and Cash Equivalents: Not disclosed
Debt: Not disclosed
Consolidated Results:
Revenue from Operations: ₹1,063.84 (Q1 FY27) vs ₹1,190.29 (Q1 FY26) - 10.6% YoY decrease
Total Income: ₹1,063.84 (Q1 FY27) vs ₹1,190.29 (Q1 FY26) - 10.6% YoY decrease
Net Profit: ₹80.73 (Q1 FY27) vs ₹109.04 (Q1 FY26) - 26.0% YoY decrease
EPS: Not specified in consolidated results
Other Equity: Not disclosed
Cash and Cash Equivalents: Not disclosed
Debt: Not disclosed
Segment-wise Performance:
The Group operates in a single business segment i.e. "manufacturing of nutritional products" as per Ind AS 108.
Corporate Actions:
- Recommended a final dividend of ₹0.30 per equity share of face value of ₹1/- each for FY26
- Record date for dividend: September 15, 2026 (subject to shareholder approval at AGM)
- Conversion of Compulsorily Convertible Preference Shares (CCPS) into equity shares on April 20, 2026
- Completed IPO through 100% Offer for Sale of 3,08,59,704 equity shares at ₹45 per share (aggregating ₹138.87 crores) on June 12, 2026
- Dissolution of IPO Committee with immediate effect
Other Significant Information:
- 33rd Annual General Meeting to be held on September 22, 2026 through VC/OAVM
- Book closure for AGM: September 16, 2026 to September 22, 2026
- Subsequent to quarter end, initiated phased decommissioning and operational restructuring of Premix manufacturing facility at Nashik, Maharashtra (no financial impact on Q1 results)
- The consolidated results include five wholly owned subsidiaries:
1. Hexagon Nutrition (International) Private Limited (India)
2. Hexagon Nutrition Healthcare Private Limited (India)
3. Hexagon Nutrition Proprietary Ltd. (South Africa)
4. Hexagon Nutrition LLC (Uzbekistan)
5. Hexagon Nutrition China Ltd. (Hong Kong)
- Merger of Hexagon Nutrition (Exports) Private Limited with Holding Company effective April 1, 2025 (appointed date)
- Results available on company website (www.hexagonnutrition.com) and stock exchange websites